{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:04:45Z","timestamp":1794891885983,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Propionic acidemia\/aciduria (PA) is an ultra-rare, life-threatening, inherited metabolic disorder caused by deficiency of the mitochondrial enzyme, propionyl-CoA carboxylase (PCC) composed of six alpha (PCCA) and six beta (PCCB) subunits. We herein report an enzyme replacement approach to treat PA using a combination of two messenger RNAs (mRNAs) (dual mRNAs) encoding both human PCCA (hPCCA) and PCCB (hPCCB) encapsulated in biodegradable lipid nanoparticles (LNPs) to produce functional PCC enzyme in liver. In patient fibroblasts, dual mRNAs encoded proteins localize in mitochondria and produce higher PCC enzyme activity vs. single (PCCA or PCCB) mRNA alone. In a hypomorphic murine model of PA, dual mRNAs normalize ammonia similarly to carglumic acid, a drug approved in Europe for the treatment of hyperammonemia due to PA. Dual mRNAs additionally restore functional PCC enzyme in liver and thus reduce primary disease-associated toxins in a dose-dependent manner in long-term 3- and 6-month repeat-dose studies in PA mice. Dual mRNAs are well-tolerated in these studies with no adverse findings. These studies demonstrate the potential of mRNA technology to chronically administer multiple mRNAs to produce large complex enzymes, with applicability to other genetic disorders.<\/jats:p>","DOI":"10.1038\/s41467-020-19156-3","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T06:04:15Z","timestamp":1603260255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Lei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Laureano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jacquinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Frassetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fortucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Hoar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmin","family":"Mihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tunkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Presnyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry E.","family":"Benenato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lukacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo G. V.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-2517","authenticated-orcid":false,"given":"Lin T.","family":"Guey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"19156_CR1","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","volume":"21","author":"D An","year":"2017","unstructured":"An, D. et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep. 21, 3548\u20133558 (2017).","journal-title":"Cell Rep."},{"key":"19156_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","volume":"24","author":"L Jiang","year":"2018","unstructured":"Jiang, L. et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat. Med. 24, 1899\u20131909 (2018).","journal-title":"Nat. Med."},{"key":"19156_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ymthe.2017.12.024","volume":"26","author":"MG Prieve","year":"2018","unstructured":"Prieve, M. G. et al. Targeted mRNA therapy for ornithine transcarbamylase deficiency. Mol. Ther. 26, 801\u2013813 (2018).","journal-title":"Mol. Ther."},{"key":"19156_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates. Am. J. Hum. Genet. 104, 625\u2013637 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"19156_CR5","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"19156_CR6","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/gt.2016.46","volume":"23","author":"F DeRosa","year":"2016","unstructured":"DeRosa, F. et al. Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther. 23, 699\u2013707 (2016).","journal-title":"Gene Ther."},{"key":"19156_CR7","doi-asserted-by":"publisher","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","volume":"114","author":"S Ramaswamy","year":"2017","unstructured":"Ramaswamy, S. et al. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc. Natl Acad. Sci. USA 114, E1941\u2013E1950 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"19156_CR8","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","volume":"36","author":"S John","year":"2018","unstructured":"John, S. et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 36, 1689\u20131699 (2018).","journal-title":"Vaccine"},{"key":"19156_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler, C. R. et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 23, 815\u2013817 (2017).","journal-title":"Nat. Med."},{"key":"19156_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10545-013-9621-3","volume":"37","author":"T Zwickler","year":"2014","unstructured":"Zwickler, T. et al. Usefulness of biochemical parameters in decision-making on the start of emergency treatment in patients with propionic acidemia. J. Inherit. Metab. Dis. 37, 31\u201337 (2014).","journal-title":"J. Inherit. Metab. Dis."},{"key":"19156_CR11","unstructured":"Adam, M. P. et al. GeneReviews\u00ae (University of Washington, Seattle, WA, 1993)."},{"key":"19156_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ymgme.2017.10.002","volume":"122","author":"P Wongkittichote","year":"2017","unstructured":"Wongkittichote, P., Mew, N. & Chapman, K. A. Propionyl-CoA carboxylase\u2014a review. Mol. Genet. Metab. 122, 145\u2013152 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"19156_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ymgme.2011.09.022","volume":"105","author":"L Pena","year":"2012","unstructured":"Pena, L. et al. Natural history of propionic acidemia. Mol. Genet. Metab. 105, 5\u20139 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"19156_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-6","volume":"8","author":"SC Gr\u00fcnert","year":"2013","unstructured":"Gr\u00fcnert, S. C. et al. Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patients. Orphanet J. Rare Dis. 8, 6 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"19156_CR15","first-page":"1041","volume":"38","author":"S K\u00f6lker","year":"2015","unstructured":"K\u00f6lker, S. et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: initial Present. J. Inherit. Metab. Dis. 38, 1041\u20131057 (2015).","journal-title":"Part 1: initial Present. J. Inherit. Metab. Dis."},{"key":"19156_CR16","first-page":"1059","volume":"38","author":"S K\u00f6lker","year":"2015","unstructured":"K\u00f6lker, S. et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: Evol. Clin. phenotype. J. Inherit. Metab. Dis. 38, 1059\u20131074 (2015).","journal-title":"Part 2: Evol. Clin. phenotype. J. Inherit. Metab. Dis."},{"key":"19156_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nature09302","volume":"466","author":"CS Huang","year":"2010","unstructured":"Huang, C. S. et al. Crystal structure of the \u03b16\u03b26 holoenzyme of propionyl-coenzyme A carboxylase. Nature 466, 1001 (2010).","journal-title":"Nature"},{"key":"19156_CR18","doi-asserted-by":"publisher","first-page":"27719","DOI":"10.1074\/jbc.M413281200","volume":"280","author":"H Jiang","year":"2005","unstructured":"Jiang, H., Rao, S. K., Yee, V. C. & Kraus, J. P. Characterization of four variant forms of human propionyl-CoA carboxylase expressed in Escherichia coli. J. Biol. Chem. 280, 27719\u201327727 (2005).","journal-title":"J. Biol. Chem."},{"key":"19156_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/(SICI)1098-1004(199910)14:4<275::AID-HUMU1>3.0.CO;2-N","volume":"14","author":"M Ugarte","year":"1999","unstructured":"Ugarte, M. et al. Overview of mutations in the PCCA and PCCB genes causing propionic acidemia. Hum. Mutat. 14, 275\u2013282 (1999).","journal-title":"Hum. Mutat."},{"key":"19156_CR20","first-page":"889","volume":"35","author":"LA Wah","year":"1983","unstructured":"Wah, L. A. et al. Assignment of the alpha and beta chains of human propionyl-CoA carboxylase to genetic complementation groups. Am. J. Hum. Genet. 35, 889\u2013899 (1983).","journal-title":"Am. J. Hum. Genet."},{"key":"19156_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ymgme.2011.09.026","volume":"105","author":"KA Chapman","year":"2012","unstructured":"Chapman, K. A. et al. Acute management of propionic acidemia. Mol. Genet. Metab. 105, 16\u201325 (2012).","journal-title":"Mol. Genet. Metab."},{"key":"19156_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0406-2","volume":"11","author":"V Valayannopoulos","year":"2016","unstructured":"Valayannopoulos, V. et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. Orphanet J. Rare Dis. 11, 32 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"19156_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.ejhg.5200442","volume":"8","author":"C P\u00e9rez-Cerd\u00e1","year":"2000","unstructured":"P\u00e9rez-Cerd\u00e1, C. et al. Potential relationship between genotype and clinical outcome in propionic acidaemia patients. Eur. J. Hum. Genet. 8, 187\u2013194 (2000).","journal-title":"Eur. J. Hum. Genet."},{"key":"19156_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0130-8","volume":"9","author":"MR Baumgartner","year":"2014","unstructured":"Baumgartner, M. R. et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J. Rare Dis. 9, 130 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"19156_CR25","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1111\/tri.12677","volume":"28","author":"C Arrizza","year":"2015","unstructured":"Arrizza, C. et al. Reversal of cardiomyopathy in propionic acidemia after liver transplantation: a 10-year follow-up. Transpl. Int. 28, 1447\u20131450 (2015).","journal-title":"Transpl. Int."},{"key":"19156_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpeds.2009.07.002","volume":"156","author":"S Romano","year":"2010","unstructured":"Romano, S. et al. Cardiomyopathies in propionic aciduria are reversible after liver transplantation. J. Pediatr. 156, 128\u2013134 (2010).","journal-title":"J. Pediatr."},{"key":"19156_CR27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/lt.25304","volume":"24","author":"K Critelli","year":"2018","unstructured":"Critelli, K. et al. Liver transplantation for propionic acidemia and methylmalonic acidemia: perioperative management and clinical outcomes. Liver transpl. 24, 1260\u20131270 (2018).","journal-title":"Liver transpl."},{"key":"19156_CR28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/ajt.13027","volume":"15","author":"F Charbit-Henrion","year":"2015","unstructured":"Charbit-Henrion, F. et al. Early and late complications after liver transplantation for propionic acidemia in children: a two centers study. Am. J. Transplant. 15, 786\u2013791 (2015).","journal-title":"Am. J. Transplant."},{"key":"19156_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.15420\/ecr.2011.7.3.220","volume":"7","author":"A Barison","year":"2011","unstructured":"Barison, A. et al. Troponin in non-ischaemic dilated cardiomyopathy. Eur. Cardio. Rev. 7, 220 (2011).","journal-title":"Eur. Cardio. Rev."},{"key":"19156_CR30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/mt.2013.68","volume":"21","author":"AJ Guenzel","year":"2013","unstructured":"Guenzel, A. J. et al. Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. Mol. Ther. 21, 1316\u20131323 (2013).","journal-title":"Mol. Ther."},{"key":"19156_CR31","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4049\/immunohorizons.1900029","volume":"3","author":"G Besin","year":"2019","unstructured":"Besin, G. et al. Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties. ImmunoHorizons 3, 282\u2013293 (2019).","journal-title":"ImmunoHorizons"},{"key":"19156_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","volume":"45","author":"D An","year":"2019","unstructured":"An, D. et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia. EBioMedicine 45, 519\u2013528 (2019).","journal-title":"EBioMedicine"},{"key":"19156_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1045-1","volume":"14","author":"T-HH Chu","year":"2019","unstructured":"Chu, T.-H. H. et al. Methylmalonic acidemia\/propionic acidemia\u2014the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet J. Rare Dis. 14, 73 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"19156_CR34","unstructured":"Manoli, I. et al. Surrogate biomarkers to assess efficacy of liver-directed genomic therapies in methylmalonic and propionic acidemias. Program #413\/F presented at the 69th Annual Meeting of The American Society of Human Genetics (Houston, Texas, 2019)."},{"key":"19156_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/hum.2014.126","volume":"26","author":"AJ Guenzel","year":"2015","unstructured":"Guenzel, A. J., Collard, R., Kraus, J. P., Matern, D. & Barry, M. A. Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors. Hum. Gene Ther. 26, 153\u2013160 (2015).","journal-title":"Hum. Gene Ther."},{"key":"19156_CR36","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","volume":"68","author":"P Berraondo","year":"2019","unstructured":"Berraondo, P., Martini, P. G., Avila, M. A. & Fontanellas, A. Messenger RNA therapy for rare genetic metabolic diseases. Gut 68, 1323\u20131330 (2019).","journal-title":"Gut"},{"key":"19156_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","volume":"40","author":"J Baruteau","year":"2017","unstructured":"Baruteau, J. et al. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. J. Inherit. Metab. Dis. 40, 497\u2013517 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"19156_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.04.007","volume":"96","author":"L Gallego-Villar","year":"2016","unstructured":"Gallego-Villar, L. et al. In vivo evidence of mitochondrial dysfunction and altered redox homeostasis in a genetic mouse model of propionic acidemia: implications for the pathophysiology of this disorder. Free Radic. Biol. Med. 96, 1\u201312 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"19156_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymgme.2017.07.009","volume":"122","author":"A Rivera-Barahona","year":"2017","unstructured":"Rivera-Barahona, A. et al. Treatment with antioxidants ameliorates oxidative damage in a mouse model of propionic acidemia. Mol. Genet. Metab. 122, 43\u201350 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"19156_CR40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1373\/clinchem.2007.101949","volume":"54","author":"C Turgeon","year":"2008","unstructured":"Turgeon, C. et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin. Chem. 54, 657\u2013664 (2008).","journal-title":"Clin. Chem."},{"key":"19156_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/8904_2012_205","volume":"10","author":"X Fu","year":"2013","unstructured":"Fu, X., Xu, Y.-K., Chan, P. & Pattengale, P. K. Simple, fast, and simultaneous detection of plasma total homocysteine, methylmalonic acid, methionine, and 2-methylcitric acid using liquid chromatography and mass spectrometry (LC\/MS\/MS).JIMD Rep. 10, 69\u201378 (2013).","journal-title":"JIMD Rep."},{"key":"19156_CR42","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1373\/clinchem.2007.087775","volume":"53","author":"G la Marca","year":"2007","unstructured":"la Marca, G. et al. Rapid 2nd-tier test for measurement of 3-OH-propionic and methylmalonic acids on dried blood spots: reducing the false-positive rate for propionylcarnitine during expanded newborn screening by liquid chromatography\u2013tandem mass spectrometry. Clin. Chem. 53, 1364\u20131369 (2007).","journal-title":"Clin. Chem."},{"key":"19156_CR43","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/clinchem\/24.11.2044","volume":"24","author":"M Pesh-Imam","year":"1978","unstructured":"Pesh-Imam, M., Kumar, S. & Willis, C. Enzymatic determination of plasma ammonia: evaluation of Sigma and BMC Kits. Clin. Chem. 24, 2044\u20132046 (1978).","journal-title":"Clin. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19156-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19156-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19156-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:30:37Z","timestamp":1670272237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19156-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["19156"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-19156-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"14 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of, and receive salary and stock options from, Moderna, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5339"}}